Business Context and Reporting Period
Company: MUSTANG BIO, INC. (MBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on developing CAR T-cell therapies and oncolytic viruses for solid tumors, specifically malignant brain tumors. The company is a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and has not generated any product revenue to date.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1.1) million | $(2.0) million | $(0.9) million |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.30) | $(0.27) |
| Cash and Cash Equivalents (End of Period) | $15.2 million | $15.2 million | $12.7 million |
| Total Assets | $15.6 million | $15.6 million | $17.6 million |
| Total Liabilities | $8.1 million | $8.1 million | $8.1 million |
| Stockholders' Equity | $7.5 million | $7.5 million | $9.5 million |
| Accumulated Deficit | $(400.7) million | $(400.7) million | $(398.6) million |
Operating Expenses (YTD 2026): Total operating expenses were $2.2 million, comprised of $0.4 million in Research and Development (R&D) and $1.8 million in General and Administrative (G&A) expenses.
Cash Flow (YTD 2026): Net cash used in operating activities was $2.0 million. There were no cash flows from investing activities. Net cash used in financing activities was $0.1 million, primarily due to offering costs.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the six months ended June 30, 2026, increased to $2.0 million from $0.9 million in the same period in 2025. This increase is primarily attributed to the absence of non-recurring gains in the current period that benefited the prior year, specifically a $0.4 million gain from lease termination and $0.8 million in savings from the settlement of aged payables recognized in 2025.
- Operating Expenses: Total operating expenses increased by 96% year-over-year (from $1.1 million to $2.2 million). R&D expenses increased significantly due to the lack of the aforementioned non-recurring savings in the current period. G&A expenses decreased slightly by 9% due to lower stock-based compensation.
- Liquidity: Cash balances decreased by $2.1 million during the six-month period, reflecting the net loss and operating cash burn, offset slightly by interest income.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance:
- The company expects to continue incurring significant operating losses for the foreseeable future and may never achieve profitability.
- Management believes it has sufficient cash to fund operations for at least twelve months from the filing date.
- Pipeline Update: The company is exploring the initiation of an investigator-sponsored clinical trial for MB-109 (combination of MB-101 CAR T and MB-108 oncolytic virus) for glioblastoma in the fourth quarter of 2026.
Material Risks and Contingencies:
- Nasdaq Delisting Risk: The company received notice from Nasdaq on April 15, 2026, regarding non-compliance with the minimum bid price requirement (Rule 5550(a)(2)) as the stock closed below $1.00 for 30 consecutive days. The company has a 180-day grace period to regain compliance by October 12, 2026. Failure to comply may result in delisting.
- Market Value of Listed Securities (MVLS): The company's MVLS is currently below the $5 million threshold for a new Nasdaq rule. If this rule becomes effective, the company could face immediate suspension and delisting without a cure period.
- Capital Requirements: The company is subject to "baby shelf rules" (General Instruction I.B.6 to Form S-3), limiting the amount of securities it can sell in a 12-month period to one-third of its public float until the float exceeds $75 million.
- Related Party Transactions: The company relies on Fortress Biotech for management services and office space. Fortress controls a voting majority of the company and receives an annual stock dividend (2.5% of fully-diluted equity), causing dilution to other shareholders.
Unusual Items:
- Lease Termination: In February 2025, the company terminated its Plantation Street Facility lease, resulting in a one-time gain of approximately $0.4 million recorded in R&D expenses in the prior year. This gain is not present in the current period.
- Payable Settlement: In 2025, the company recognized $0.8 million in savings from the settlement of aged payables, which reduced expenses in the prior period but is not applicable to the current period.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify the company's progress in regaining compliance with the $1.00 minimum bid price requirement by the October 12, 2026 deadline to avoid delisting.
- Cash Runway: Confirm the sufficiency of the $15.2 million cash balance to fund operations through the planned Q4 2026 clinical trial initiation and beyond, given the lack of revenue.
- Capital Raising Constraints: Assess the impact of the "baby shelf rules" on the company's ability to raise necessary capital given its current public float is under $75 million.
- Related Party Dilution: Review the impact of the annual 2.5% stock dividend paid to Fortress Biotech on shareholder equity dilution.
- Clinical Trial Timeline: Monitor the status of the MB-109 investigator-sponsored trial planned for Q4 2026, as delays could significantly impact the company's value proposition and funding needs.